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Abstract: Pulmonary arterial hypertension (PAH) is a multi-factorial disease characterized by the
hyperproliferation of pulmonary artery smooth muscle cells (PASMCs). Excessive reactive oxygen
species (ROS) formation resulted in alterations of the structure and function of pulmonary arterial
walls, leading to right ventricular failure and death. Diabetes mellitus has not yet been implicated in
pulmonary hypertension. However, recently, variable studies have shown that diabetes is correlated
with pulmonary hypertension pathobiology, which could participate in themodification of pulmonary
artery muscles. Themetabolomic changes in PASMCswere studied in response to 25mM of D-glucose
(high glucose, or HG) in order to establish a diabetic-like condition in an in vitro setting, and compared
to five mM of D-glucose (normal glucose, or LG). The effect of co-culturing these cells with an ideal
blood serum concentration of cholecalciferol-D3 and tocopherol was also examined. The current study
aimed to examine the role of hyperglycemia in pulmonary arterial hypertension by the quantification
and detection of the metabolomic alteration of smooth muscle cells in high-glucose conditions.
Untargeted metabolomics was carried out using hydrophilic interaction liquid chromatography and
high-resolution mass spectrometry. Cell proliferation was assessed by cell viability and the [3H]
thymidine incorporation assay, and the redox state within the cells was examined by measuring
reactive oxygen species (ROS) generation. The results demonstrated that PASMCs in high glucose
(HG) grew, proliferated faster, and generated higher levels of superoxide anion (O2·
−) and hydrogen
peroxide (H2O2). The metabolomics of cells cultured in HG showed that the carbohydrate pathway,
especially that of the upper glycolytic pathway metabolites, was influenced by the activation of
the oxidation pathway: the pentose phosphate pathway (PPP). The amount of amino acids such
as aspartate and glutathione reduced via HG, while glutathione disulfide, N6-Acetyl-L-lysine,
glutamate, and 5-aminopentanoate increased. Lipids either as fatty acids or glycerophospholipids
were downregulated in most of the metabolites, with the exception of docosatetraenoic acid and PG
(16:0/16:1(9Z)). Purine and pyrimidine were influenced by hyperglycaemia following PPP oxidation.
The results in addition showed that cells exposed to 25 mM of glucose were oxidatively stressed
comparing to those cultured in five mM of glucose. Cholecalciferol (D3, or vitamin D) and tocopherol
(vitamin E) were shown to restore the redox status of many metabolic pathways.
Keywords: oxidative stress; pulmonary arterial hypertension; smooth muscle cells; metabolomics;
metabolic profiling; diabetes mellitus; hyperglycaemia; vitamin D; vitamin E
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1. Introduction
Pulmonary artery hypertension (PAH) is a disease characterized by an increase in mean pulmonary
arterial pressure by more than 25 mmHg, as well as vasoconstriction and vascular obstruction.
This in turn increases pulmonary vascular resistance and right ventricular failure. Various factors
contribute to pulmonary hypertension, so it is difficult to understand the mechanisms that initiate
and develop the disease. Although knowledge of disease pathogenesis and treatment has greatly
improved, the mortality rate is still high among PAH patients [1], and the survival of patients is
significantly influenced, despite the classification of the disease [2,3]. The clinical diagnosis and
treatment of PAH depends on the disease classification based on the “updated clinical classification
of pulmonary hypertension”, while a comorbid condition such as hyperglycemia has not been taken
into consideration yet [4]. The United Kingdom (UK) and Ireland pulmonary hypertension registry
data shows that more than 20% of pulmonary hypertension (PH) patients above 50 years old had
diabetes [5]. These data are associated with the combined data of four pulmonary hypertension centers
that assessed diabetes mellitus for those who were newly diagnosed with PH, and found that 107 out
of 415 pulmonary hypertension patients had diabetes [6,7]. On top of that, mortality was found to
be higher among diabetic pulmonary hypertension patients compared to non-diabetic patients [6],
indicating that hyperglycemia could adversely contribute to the PAH patients’ survival. Another study
that investigated the survival of PAH patients with and without diabetes mellitus (DM) found that
DM patients had 10 years lower survival than PAH patients without DM [7].
Based on that and other studies [8,9] that found glucose intolerance, insulin resistance,
and metabolic syndrome influenced PAH, it can be hypothesized that hyperglycemia could disturb the
metabolic pathway of PASMCs, leading to medial hypertrophy, fibrosis, proliferation, vessel thickness,
and vascular inflammation and remodeling, leading eventually to right ventricular failure.
The study aimed to examine the alteration of the metabolomic profile that occurs in the pulmonary
artery smooth muscle cells following an increase in glucose concentration, and the effect of antioxidant
treatments such as cholecalciferol (D3, or vitamin D) or tocopherol (vitamin E) on the metabolomics of
PASMCs during diabetic-likes conditions.
Evidence indicates that high glucose levels stimulate the overproduction of the reactive oxygen
species (ROS) of vascular cells, which is considered to be strong contributor to the oxidative stress
involved in the pathogenesis of subsequent complications in cardiovascular diseases [10]. Sustained
exposure to elevated glucose levels enhances the production of reactive species in the heart and
macrovascular system, and stimulates in turn fatty acid oxidation [10]. The overproduction of ROS by
the mitochondria due to more glucose being oxidized in the trichloroacetic acid (TCA) cycle drives the
mechanisms that are responsible for tissue damage [11]. Superoxide (O2·
−) is the primary form of the
mitochondrial free radical that transforms to other reactive species, leading to cell damage [12].
The overproduction of reactive species ultimately influences living organisms, as they interfere
with cell DNA, lipids, and proteins, leading to mutation due to negative gene–environment
interactions [13]. Cardiovascular diseases, diabetes, and neurodegeneration are the most common
consequences of increased DNA oxidation. Increased lipid and protein oxidative damage in diabetes
patients are associated with disease complications [14,15].
Glutathione (GSH) is an important and abundant endogenous that preserves the redox state of
the thiol groups (R-SH) of proteins, which are essential for the restoration and expression of DNA.
It serves as a scavenger of OH· and superoxide, detoxifies H2O2 and lipid peroxides, and supports
the recycling of vitamins C and E [16]. A decrease in the cellular concentration of reduced GSH and
glutathione metabolism impairment as a result of a reduction in cysteine and glycine, which are the
precursors necessary to synthesize glutathione, has been correlated with diabetes [17,18]. Chronic
hyperglycemia produces oxidative stress via the competition between glutathione reductase and
aldose reductase for nicotinamide adenine dinucleotide phosphate reduced form NADPH, resulting in
decreased GSH restoration from its oxidized form and a decreased ratio of NADPH/NADP (Oxidized
form of nicotinamide adenine dinucleotide phosphate) [19].
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ROS also obstructs glycolytic enzymes such as glyceraldehyde 3-phosphate dehydrogenase,
phosphofructokinase-1, and pyruvate kinaseM2. Proportionally, glycolytic inhibition diverts glycolysis
toward the pentose phosphate pathway (PPP) oxidative arm to generate NADPH, which recycles
oxidized glutathione as an antioxidant response to the oxidative stress (Figures 1 and 2).
Figure 1. The rerouting of glucose flux into the pentose phosphate pathway (PPP) due to oxidative
stress. Glycolysis was encouraged, while the activation of PPP by reactive oxygen species enhances the
production of NADPH from NADP+.
 
Figure 2. The oxidative branch of the PPP is a major supplier of NADPH for glutathione recycling.
The reduction of glutathione (GSH) disulfide to glutathione via glutathione reductase needs NADPH
to be completed. Thus, oxidized glutathione (GSSG):GSH and NADPH:NADP+ ratios are impaired
due to oxidative stress.
A decrease in the GSH/oxidized glutathione (GSSG) ratio has been reported as an oxidative stress
marker. A study that observed the serum glutathione levels of diabetes patients found lower levels of
GSH compared to control subjects [20].
ROS in addition can damage proteins, causing a loss of protein catalytic activity, and driving them
to become more susceptible to proteolytic degradation [21].
Lipids also are vulnerable targets of ROS, as their molecular structures have abundant reactive
double bonds [22]. Reactive species cause lipid peroxidation and disrupt the lipid bilayer, and this
may deactivate membrane-bound receptors and enzymes, leading to a loss of membrane fluidity,
elasticity, permeability, impaired cellular function, and cell lysis. Lipid peroxidation leads to products
such as malondialdehyde (MDA), isoprostanes, and 4-hydroxynonenal. These have been identified
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as significant oxidative stress biomarkers, and are able to deactivate various cellular proteins by the
formation of protein cross-links.
MDA is a reactive carbonyl compound that is known to be mutagenic, atherogenic, and carcinogenic.
Its reaction with lysine residues forms lysine–lysine cross-links, which have been detected in
apolipoprotein B (apoB) fragments of oxidized low-density lipoprotein (oxLDL), and has been
hypothesized to interrupt the interaction between oxLDL and macrophages, and thereby enhance
atherosclerosis [23].
Antioxidants
Vitamins D and E have been shown to have antioxidant properties [24]. The serum levels of
25-hydroxy vitamin D are found to be deficient among type 2 diabetic patients [24,25]. Animal models
and clinical trial studies have demonstrated the ability of vitamin D to reduce oxidative markers [26,27].
Vitamin E is a lipid-soluble antioxidant that scavenges lipid radicals. It has been reported that the
incidence of primary major coronary events among subjects who received vitamin E decreased by 4%
compared to a control group receiving placebo, and the incidence of primary major coronary events
decreased by 8% [28]. However, other trial studies indicated that the efficacy of vitamin E in reducing
the number of major cardiovascular incidents did not influence total mortality [29,30]. The current
study aimed to investigate the role of both vitamin E and D as antioxidants, and examine their effects
on the smooth muscle cell metabolome in the presence of high-glucose media.
2. Results
2.1. Effect of High-Glucose Media Alone, with Vitamin D, or with Vitamin E, on Cell Viability
Prior to cell extraction preparation for LC/MS, the high and normal glucose cultured cells and
the treated cells were counted using trypan blue exclusion at the end of the 72-h experimental period
(Figure 3). This demonstrated that viable cell numbers were substantially increased by the high-glucose
(HG) culture medium (14.9 ± 0.67% versus normal glucose, or LG). Treating pulmonary artery smooth
muscle cells (PASMCs) with vitamin E or vitamin D decreased cell numbers almost to the level of the
normal glucose medium (by 11.5 ± 0.4% or by 10.1 ± 2.3% versus HG), respectively.
 
ȣ
Figure 3. The effect of vitamin D/vitamin E in high glucose-induced pulmonary artery smooth muscle
cells (PASMC) proliferation. Cells were cultured with normal glucose (five mM) and high glucose
(25 mM) for 72 h. Vitamin D (80 ng/mL) and Vitamin E (9 µg/mL) were added immediately along with
the high-glucose incubation. Cells were stained with trypan blue dye, and the viable cells were counted
after 72 h. Each value represents the mean ± SEM from four independent experiments. * p < 0.05 vs.
cells cultured in normal glucose (five mM) media. • p < 0.05 vs. high glucose stimulated cells. ANOVA
one way followed by Tukey’s comparison test was performed.
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2.2. Effect of High-Glucose Media Alone, with Vitamin D, or with Vitamin E on PASMCs’ Proliferation
The proliferative capacity of high-glucose media and the combined effects of high glucose with
vitamin D/or with vitamin E on cell proliferation were assessed by the [3H] thymidine incorporation
assay. High-glucose media increased DNA synthesis in PASMCs by (14.4 ± 3.19% versus LG), while
vitamin D and vitamin E were significantly able to suppress the DNA synthesis of cells cultured in
high glucose by (5.3 ± 2.8% and 15.6 ± 4%, versus HG), respectively (Figure 4). Cell counting and
proliferation quantification showed that for cells cultured at matching density and examined (counting
or assayed) at the same time point of 72 h, the PASMCs in the HG media steadily revealed a noticeably
superior proliferation rate.
ȣ
ƺ
ȝ ȝ
ƺ
Figure 4. The effect of vitamin D and vitamin E on high glucose-induced [3H] thymidine uptake by
PASMCs. Quiesced cells were cultured with normal (five mM) and high glucose (25 mM) for 72 h.
Vitamin D (80 ng/mL) and vitamin E (9 µg/mL) were added immediately along with high-glucose
incubation. [3H]-thymidine incorporation assay was performed for the evaluation of DNA synthesis
(as an index of cell proliferation). Radioactive counts were measured in disintegrations per minutes
(DPMs) ± SEM. * p < 0.05 vs. cells cultured in normal glucose (five mM) media. • p < 0.05 vs. high
glucose cultured cells (n = 4). ANOVA one way followed by Tukey’s comparison test were performed.
(+ve) control: cells placed in culture of ordinary environment with no adjusted glucose and 10%
bovine serum.
2.3. Evaluation of Oxidative Stress
The measurement of ROS was carried out to determine whether or not the high concentration
of glucose in the cultured media enhanced oxidative stress activity within the cells. In addition,
ROS levels were also evaluated following the combined effects of HG media supplemented with
vitamin D/and with vitamin E.
Intracellular superoxide (O2·
−) levels and hydrogen peroxide (H2O2) release within the PASMCs
were measured by dihydroethidium (DHE) and 2′, 7′-dichlorofluorescein (DCF), respectively.
The results showed that PASMCs cultured in HGmedia significantly generated higher ROS (superoxide
and H2O2) levels in comparison to cells cultured in LG media. Interestingly, adding vitamin D or E to
the high glucose-cultured cells significantly reduced the intracellular superoxide levels, while no effect
was noticed on hydrogen peroxide (Figure 5). So, they were able to reduce the primary ROS product
(O2·
−), but not the secondary ROS product (H2O2).
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Figure 5. The effect of high-glucose media alone, with vitamin D, and with vitamin E on reactive
oxygen species (ROS) production. PASMC cells were incubated with normal (five mM) and high
glucose (25 mM) for 72 h. Vitamin D (80 ng/mL) and vitamin E (nine µg/mL) were added immediately
along with high-glucose incubation. Superoxide (O2·
−) levels and hydrogen peroxide (H2O2) levels
were detected by dihydroethidium (DHE) and 2′, 7′-dichlorofluorescein (DCF) fluorescence compound,
respectively. * p < 0.05 vs. unstimulated cells (n = 4). * p < 0.05 vs. cells cultured in normal glucose
(five mM) media. • p < 0.05 vs. high-glucose cultured cells n = 4). ANOVA one-way followed by
Tukey’s comparison test was performed. (+ve) control: cells were treated by ROS inducer agents.
2.4. Metabolomics
LC/MS analysis was carried out where the samples were prepared and injected, and data
afterwards was extracted and processed to identify all of the biochemical (metabolite) markers changed
by HG media comparing to control (LG). Then, the impact of adding vitamin D and vitamin E on HG
media were also measured on those altered metabolites. Triplicate samples were prepared for each
group, and only consistent metabolites alterations were listed.
2.4.1. Quality Control Samples (Pooled)
To measure the precision of the instrument, the relative standard deviation (RSD) was calculated
based on the reading of a pooled sample, which was injected five times during the course of the
run and clustered together in the principal components analysis (PCA) plot (Figure 6). An RSD was
calculated based on the total intensities in each sample, and an RSD of 19.58% was obtained. RSD was
then calculated individually for each putative metabolite in the pooled sample, and the highest RSD
was for oxoglutarate (138%) followed by ornaline (91%), while glutamine had the lowest RSD value
(0.076%). The precision of these values clearly indicates that any metabolic differences between the
groups cannot be due to instrumental factors alone. Metabolites with RSD values higher than 20%
were excluded before the model was fitted by using Umetrics multivariate tool multivariant analysis
application (SIMCA-P).
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Figure 6. Principal components analysis (PCA) score plot for quality control (QC) (pooled) cell extract
samples of (PASMCs). P1, P2, P3, P4, and P5 represent the quality control sample runs frequently
throughout the experiment.
2.4.2. Visualization and Biomarkers Identification
Principle component analysis (PCA) was employed to observe the possible presence of outliers,
groups, similarities, and other patterns in the data. Afterward, Orthogonal Projections to Latent
Structures Discriminant Analysis (OPLS-DA) was used to understand the differences between groups
and identify the biomarkers that distinguish the groups from one another.
The PCA plot in Figure 7 shows the separation between groups of cells cultured in vitamins D
and E, and another two groups cultured in high and normal glucose alone. No clear separation can be
seen between the normal (LG) and high (HG) glucose groups (Figure 7A). However, clustering became
clearer when OPLS-DA supervised analysis was applied.
Figure 7. (A) Principal components analysis (PCA) plot, (B) Orthogonal Projections to Latent Structures
Discriminant Analysis (OPLS-DA) plot for groups of normal glucose (five mM glucose), high glucose
(25 mM glucose), vitamin D, and vitamin E. The plot shows the distribution of 12 samples based on the
reading of 549 putative metabolites.
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The OPLS-DA model shows a clear clustering pattern in which each group was able to gather, as
can be seen in Figure 7B. Even though samples were clustered, goodness of prediction was high at
0.99, and the model fit was good (72% predictive, 23% orthogonal), the cross-validated (CV)-ANOVA
of the model (p = 0.885) indicated that the model was not valid (Table 1).
Table 1. The validity of the model shown in Figure 7B, where the P value was above 0.05.
Model SS DF MS F p Value SD
Total corr. 33 33 1 - - 1
Regression 27.15 30 0.905 0.465028 0.885 0.9514
Residual 5.840 3 1.946 - - 1.3952
2.4.3. Effect of High-Glucose Media
In order to identify the markers that distinguish the HG and LG groups, a new model was built
comparing only samples cultured in LG and HG. The, the data were filtered based on CV-ANOVA,
with 95% confidence intervals and variables of importance for the projection (VIP) values of each of
549 features, as described in Figure S1. This workflow highlighted 80 metabolites that distinguished
the HG group from the LG group. p values < 0.05, 95% CI not including zero values, RSD <20% in the
pooled samples, and VIP values >1.
Figure 8A shows the samples clustering in the model based on 549 metabolites, while the model
fit 89% of the data (30% predictive, 59% orthogonal and CV-ANOVA, p = 0.0954). Plot (B) was then
rebuilt based on the reading of 80 significant biomarkers where the model was able to fit 86% of the
data (80% predictive, 6% orthogonal, and CV-ANOVA, p = 0.0141).
Figure 8. OPLS-DA score plots showing the effect of high-glucose media compared to normal glucose
media on the pulmonary artery smooth muscle cells. (A) Based on 549 features. (B) Based on
80 significant markers affected by hyperglycemic media.
Several lipids and lysolipids fell significantly due to high glucose, indicating that the cell
membrane composition was affected. Some amino acids were influenced too, especially lysine
degradation and biosynthesis, while in addition, oxidized glutathione (GSSG) as an oxidative damage
marker increased, and glutathione (GSH) decreased. Glycolysis metabolites were influenced as well
when particularly the pentose phosphate oxidative pathway was activated due to high-glucose flux
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into that pathway. In addition, NADH was slightly increased, while Acetyl-coA and TCA acids were
not influenced, suggesting that lower glycolysis was not as active as that at the upper site. ATP was
decreased, which may indicate that it was consumed in cell division, while the cell growth increased
when PASMCs were cultured in HG media. In addition, the majority of the nucleotides’ metabolites
were influenced by HG following the activation of pentose phosphate pathway (PPP).
2.5. Antioxidants
Metabolic profiling illustrated that using vitamins D and E attenuated the oxidative stress that
occurred through exposing PASMCs to HG.
Many of the metabolites see (Supplementary Materials, Table S1) that were altered by HG were
restored to control levels when plasma concentrations of either vitamin D or E were added. Glycolysis
metabolites that were enhanced by HG illustrated showed a contrary response when the antioxidants
were used. This effect also can be seen in oxidized and reduced glutathione, where particularly vitamin
D helps to preserve normal status. Many lipids, including fatty acids and glycerophospholipids (GPL),
were decreased by HG, but the antioxidants were not specifically effective with GPL to restore most of
the altered metabolites. Nucleotide metabolites generally increased due to HG, while antioxidants
were able to restore most of them to around normal levels.
3. Discussion
High glucose (HG) is an important cause of cardiovascular disease, which acts via various
mechanisms to enhance ROS accumulation. The accumulation of ROS successively causes cellular
impairment, which is strongly involved in diabetes complications. ROS can immediately damage
cellular components, including proteins, carbohydrates, lipids, DNA, and subsequently affect the
metabolic pathways, resulting in a shift of (PASMC) phenotype from the contractile phenotype to
a synthetic (hyperproliferative/apoptotic-resistant) phenotype, and initiating cell proliferation and
migration [31]. While, in turn, some clinical studies have found inadequate provision for the use of
antioxidants in diabetes [32–34], others have demonstrated the advantages of antioxidant usage in the
prevention of diabetic cardiovascular complications [35–37].
The current study was designed to determine the impact of HG on PASMC proliferation and ROS
generation. It focused on the abnormal changes in the cellular metabolome in order to investigate
the effect of adding the antioxidants vitamin D or E on the prevention of cell proliferation and the
oxidative damage caused by ROS generation, which could be induced by stimulating the PASMCs
with HG medium.
The data obtained from the cell viability assay demonstrated a significant increase in the number
of PASMCs by increasing the glucose concentration to 25 mM (Figure 3). This result is compatible with
the results of the [3H] thymidine incorporation assay (Figure 4), which indicated that cell proliferation
increased in response to HG, as an increase in both total cell numbers and DNA synthesis were
observed. Cell proliferation was slightly but statistically significantly induced when cells were
exposed to HG for 72 hours while, in turn, adding vitamin D or E to HG media succeeded in
inhibiting cell proliferation. These results link with many studies carried out on animal and human
cellular models [38–40], indicating that HG medium enhances pulmonary arterial smooth muscle
cell proliferation via different pathways. In contrast, the antioxidants, particularly vitamins D and
E, have been found to suppress vascular smooth muscle cells VSMCs’ proliferative activity [41–43]
through different mechanisms.
The current results also showed that HG medium not only induced cell proliferation, but also
elevated ROS levels, including both superoxide and H2O2 levels (Figure 5). Vitamin D inhibited the
overexpression of superoxide O2
− in high-glucose stimulated cells, but not H2O2, while vitamin E was
able to suppress both O2
− andH2O2 levels. Vitamin D is well-known to promote the scavenging of ROS
and diminish reactive species formation in diabetic mice by the suppression of NADPH oxidase gene
expression [44,45]. In an experiment carried out on diabetic mice, vitamins D and E decreased lipid
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peroxidation and promoted superoxide dismutase (SOD) activity [46]. Alpha-tocopherol (vitamin E)
inhibited the prevalence of peroxidation originating from reactive species, preventing undesired lipid
oxidation [47].
In the current experiment, adding physiological concentrations of vitamin E and vitamin D to the
stimulated cells had a favorable effect on most of the altered metabolites. A total of 549 metabolites
were profiled in both positive and negative modes by LC-MS, while only 80 metabolites were found
to distinguish HG samples from LG in a valid OPLS-DA model. Samples treated with vitamin E or
vitamin D were also compared to the HG group to examine their impact as antioxidants. The impact
of the antioxidants on the 80 metabolites that distinguished the LG from HG was only considered.
Vitamin E and vitamin D restored many of the metabolites affected by HG to the levels observed in LG
(Figure 9).
 
Figure 9. Changes occurred among selected metabolites due to different interventions. Most of the
glutathione hemostasis and PPP metabolites influenced by hyperglycemia responded to antioxidants
and preserved the normal levels. Pentose phosphate specifically was attenuated via vitamins D and E,
suggesting that NADPH re-equipment was decreased. (*) (CV-ANOVA < 0.05).
3.1. Glycolysis
Glucose metabolism fluctuation plays an important role increasing cellular oxidative stress and
the vascular remodeling of PAH in diabetic patients [48,49]. In the current study, although increased
levels of glucose-1-phosphate (G-1P) and glucose-6-phosphate (G-6P) were observed, as well as
increased levels of glyceraldehyde phosphate and dihydroxy acetone phosphate in HG compared
to LG, vitamin D and vitamin E had so significant effect in lowering these metabolites. HG samples
revealed higher levels of gluconate, cytidine diphosphate (CDP)-ribitol, ribitol 5-phosphate, uridine
diphosphate (UDP)-glucose, and xylulose 5-phosphate, indicating that the glucose flux was redirected
toward the PPP. The shift of glucose flux toward the PPP is compatible with increased cell proliferation,
reflecting an increased requirement for nucleotides. Stimulated smooth muscle cells activate PPP in
order to generate NADPH from NADP+ as part of an antioxidant mechanism. However, it would
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seem that the flux through the PPP is via a non-oxidative route into sedoheptulose phosphate, since
the levels of NADPH are reduced possibly as a result of excessive ROS generation, as evidenced
by an increase in GSSG levels [50]. The elevation of the non-oxidative route into sedoheptulose
phosphate is underlined by the elevation of compounds putatively identified as octulose and nonulose
phosphates, which could be formed via the action of transaldolase on fructose, ribose phosphates, and
two fructose phosphate molecules, respectively. Interestingly, phosphoglycerate was not increased
by HG, which might suggest further reinforcing the view that there was a diversion of glucose into
the PPP upstream of these metabolites. HG samples exhibited a slight increase in their NADH
levels, which indicated that the Krebs cycle was not significantly inhibited, and suggested that other
pathways such as the polyol pathway may be induced by hyperglycemia see (Figure 10). The TCA
cycle acids mainly were not increased by HG, with a decrease of citric acid and increase of fumaric
acid. Lactate in addition was slightly increased, which could also indicate that there was some
conversion of pyruvate to lactate, rather than the acetyl coenzyme A (acetyl coA) “Warburg effect”.
The accumulation of 3-phosphoglyceraldehyde (GA 3-P) was significantly increased in the HG samples,
indicating that excessive ROS generation might inhibit the conversion of most of the GA 3-P via the
glycolysis process into pyruvate. N2-(D-1-carboxyethyl)-L-lysine (CL) is a product of the reaction of
methylglyoxal (MG) with lysine residues in proteins, which occurs in diabetes, and has been proposed
to be linked to cardiovascular disease and indicates increased levels of MG. MG has been found
to inhibit glyceraldehyde phosphate dehydrogenase, thus causing the accumulation of GA 3-P and
the diversion of GA 3-P into the PPP [51]. Reaction with NADP+ and H2O in the presence of CL
dehydrogenase forms L-lysine, NADPH, and pyruvate. In the HG samples, the accumulation of CL
pointed to the inhibition of that reaction. Vitamin D and vitamin E appear to have a direct effect in
promoting the degradation of CL. Antioxidants showed no impact on the GA 3-P that was upregulated
by HG media. These findings confirm that the upper glycolysis and PPP were strongly affected by HG,
but the lower glycolysis and TCA cycle were not.
 
Figure 10. Metabolites affected by different conditions: normoglycemia (LG), hyperglycemia
(HG), with vitamin D or vitamin E. Column figures display the average intensities of specific
metabolites in different conditions. G1-P: glucose 6-phosphate; G6-P: glucose 6-phosphate; GA 3-P:
3-phosphoglyceraldehyde; F6-P: fructose 6-phosphate.
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Figure 11. Heat map visualizing the significant metabolites impacted by high glucose (HG) comparing to normal glucose (LG) conditions. Row: represents the
metabolite; Column: represents the samples group (red: normal glucose; green: high glucose); The color key specifies the metabolite intensity; lowest: dark blue;
highest: dark red.
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Under HG, the cells appear to produce glycogens with UDP glucose (their precursor) and sugar
dimers, tetramers, and pentamers being increased, indicating that the cells have the capacity for glucose
storage. ATP levels were lowered by HG, indicating that increased energy was consumed, which
may correlate with increased cell proliferation. These findings agree with different studies that have
indicated that high glucose produces oxidative stress, disturbed glucose metabolism, and impaired
the most substantial source of energy—“electron transport chain” (ETC)—activity, causing ETC
dysfunction [51–54]. Vitamin D or E attenuate many of the metabolites induced by HG; see (Figure 11).
Vitamin D decreased the level of GSSG and increased the level of GSH; this was mirrored by a further
fall in NADPH in comparison with HG, since it is consumed as a co-factor in the conversion of GSSG
to GSH. Correspondingly, GSH levels increased in the HG samples treated with vitamin D. GSH levels
also increased in the vitamin E-treated samples, but without GSH or NADPH falling, suggesting a
different mechanism for conserving GSH compared with vitamin D. HG is believed to diminish GSH
synthesis, which is reported in diabetic patients [55]. Increasing GSSG formation is associated with the
excessive generation of free radicals as a marker of oxidative stress, which are believed to be elevated
in diabetes and PAH [55,56]. Despite the decrease in ATP when antioxidants were added, NADH and
NADP+ were restored almost to their normal levels.
3.2. Amino Acids
Amino acids were generally disturbed with no clear pattern, while aspartate downregulation
may indicate an inhibition of the conversion of aspartate to pyruvate, which has been demonstrated
previously in a metabolomics-based study of pulmonary arterial hypertension [57]. Citrulline and
histidine were also downregulated, while almost all of the other amino acids were not significantly
affected, apart from glutamate and N2-(D-1-Carboxyethyl)-L-lysine, which were increased by HG. In
addition, N6-acetyllysine and aminopentanoate were influenced, indicating that the lysine degradation
pathway might be activated in order to promote the biosynthesis of acetoacetyl-CoA. Although small
changes of amino acids appeared due to HG, vitamins D and E were able to inhibit some of the induced
changes such as those for glutamate, N2-(D-1-Carboxyethyl)-L-lysine, and aminopentanoate.
3.3. Lipids
The metabolic profiling of induced PASMCs showed an alteration of lipid pathways by HG.
However, there was no clear pattern, with some lipids, especially fatty acids being upregulated and
some being downregulated by HG. The clearest effect of vitamin D and vitamin E appeared to be
in promoting increased levels of the polyunsaturated fatty acids linoleic acid, eicosatrienoic acid,
docosatetraenoic acid, and docosatrienoic acid. This might indicate that some of these acids protect
against oxidation. A study carried out on the lipid metabolism of vascular cell physiology showed that
cardiovascular diseases were associated with changes in lipid metabolism, and accordingly alterations
in lipid profiles [58]. Other studies carried out on Alzheimer’s disease revealed a significant decrease
in long-chain glycerophosphocholine (PC) (36:5; 38:6 and 40:6), sulfatides [59,60], and increases
of very long-chain lysophosphatidylcholine (LPCs) (32:0 and 34:0) [52]. Vitamin E is an effective
antioxidant reserve lipid, avoiding most lipid oxidation [53]. Vitamin D was firstly identified to work
as antioxidant in 1993, when it was shown that it had the ability to prevent lipid peroxidation in the
cell membrane [24]. However, our result demonstrated a narrow impact on specific lipids that could
show a positive response to the antioxidants, suggesting that they might of help to prevent little of the
undesired modifications occurring on the lipid metabolites due to HG.
3.4. Nucleotides
HG induced pyrimidine and purine pathwaymetabolites and increased the intracellular content of
uridine, pseudouridine, 3′-uridinemonophosphate (UMP), guanine, and hypoxanthine. PPP influences
nucleotide metabolites that are believed to modulate smooth muscle cell proliferation. Cell culture
studies on artery SMCs derived from human and rat showed that mononucleotide polyphosphates
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such as ATP and uridine-triphosphate (UTP) stimulate SMC proliferation [61]. In vitro and in vivo
studies found that increases of the intracellular content of uridine correlated with an increase in insulin
resistance [62,63]. Vitamins D and E have a marked effect on lowering uridine levels under HG. A study
that investigated biochemical oxidative markers found that hypoxanthine plasma concentration was
elevated [54] among patients of obstructive sleep apnoea syndrome, which is a disease characterized
by an increase of oxidative stress in comparison to normal subjects. However, hypoxanthine has also
been found to inhibit the proliferation of smooth muscle cells, and both antioxidant vitamins were
found to greatly increase hypoxanthine levels in the current experiment.
4. Materials and Methods
4.1. Cell Culture
Rat pulmonary artery smooth muscle cells (PASMCs) were obtained, harvested, and dissected
from Sprague–Dawley rats and cleaned independently under aseptic conditions. Small rings of the
pulmonary arteries were transferred into 25-cm2 flasks that were filled with culture media. Cells were
then supplemented by 10% bovine calf serum (BCS), 5% penicillin, and streptomycin in mixture
of 1:1 F-12: Dulbecco’s Modified Eagle’s medium (DMEM) and cultured at 37 ◦C in a 21% O2,
5% CO2 incubator. In addition, the condition of each group was prepared as follows: (1) 25 mM
of glucose for high-glucose media “diabetic-like condition”; (2) five mM of glucose for normal glucose
media (3) 25 mM of glucose + physiological concentration of vitamin D cholecalciferol (80 ng/mL) or
(4) 25 mM of glucose + physiological concentration of vitamin E α-tocopherol (9 µg/mL).
4.2. Cell Viability
PASMCs were seeded at an intensity of 14 × 104 cells/well in 25-cm2 flasks supplemented with
10% BCS DMEM overnight and allowed to attach. Next, cells were washed with free media and
cultured in 5% BCS for 72 h with appropriate glucose and antioxidant concentration based on our
intervention and the condition of each group. By the end of the incubation period, cells were harvested,
suspended, and counted using a haemocytometer cell counting chamber. Ten percent of trypan blue
was used to detect viable cells.
4.3. PASMC Proliferation Assay
Confluent PASMC were trypsinized, placed in DMEM supplemented with 10% BCS, and seeded
into 24-well flasks at a cell intensity of 2 × 104 per well. After 24 h, cells were washed by free media
and quiesced with 0.1% BCS for 24 h. Cells were then cultured in 5% BCS for 72 h with appropriate
glucose concentrations and antioxidant concentrations based on our intervention and the condition of
each group. During last six hours of the assay, [3H-thymidine] aqueous solution (GE Healthcare®) was
added to each well. In order to prepare assay samples, media were discarded and cells were rinsed
by one milliliter of cold PBS for 10 minutes and treated four times with one milliliter of 10% (w/w)
trichloroacetic acid (TCA, Sigma). Afterward, 250 µL 0.1% sodium hydroxide/sodium lauryl sulphate
(SDS) added into each well and two milliliters of Emulsifier-safe™ scintillation fluid was added to the
scintillation vial of each sample before they were mixed well prior to measuring the radioactive counts
using a scintillation counter.
4.4. Reactive Oxygen Species Experiment
PASMCs were seeded at 5 × 103 cells per well in 96-well plates supplemented with 10%
BCS DMEM for 24 h and allowed to attach. Then, the media was discarded, and the cells were
washed by free media, followed by the addition of 5% BCS DMEMmedia for 72 h with appropriate
glucose and antioxidant concentrations, based on our intervention and the condition of each
group. During the final 30 minutes of the assay, 2.0 µL of dihydroethidium (DHE) or 10 µL of
2′, 7′-dichlorfluorescein (DCF) were added to each well, and the cells were placed for 30 minutes in
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the dark before fluorescence microscopy was performed. Dihydroethidium (DHE) and 10 µL of
2′, 7′-dichlorfluorescein (DCF) are fluorogenic dyes that measure reactive oxygen species (ROS)
superoxide and hydrogen peroxide, respectively.
4.5. Metabolic Profiling Sample Preparation
In an appropriate number of replication, cells were cultured with various conditions at indicated
final concentrations with their corresponding vehicle-only controls, and incubated for 72 h. Afterward,
the medium was discarded, and the cells were twice washed with three mL of phosphate-buffered
saline (PBS) at 37 ◦C before lysis. Volumes of the extraction solution were adjusted relying
on the cell number of each condition, with one ml independently added to each 1 × 106 cells.
Cells’ flasks were then placed on ice where an appropriate volume of ice-cold extraction buffer
(methanol:acetonitrile:water 50:30:20) was added, and cells were harvested using a cell scraper. Then,
samples were vortexed for 12 minutes before they were placed into centrifuge at 0 ◦C for 15 minutes
and 15,300 (r.p.m). Supernatant was collected and placed in −20 ◦C for further liquid chromatography
mass spectrometer analysis (LC/MS). During the run, we maintained the temperature of the auto
sampler at 4 ◦C. Mixtures of standard biochemicals (Sigma-Aldrich, Poole, UK) and the pooled quality
control (QC) sample were injected throughout the analysis run in order to simplify the identification of
metabolites and assess the method’s stability and reproducibility. The QC sample was prepared by
taking equal aliquots from all of the samples and placing them into one HPLC vial.
4.6. Samples Analysis (LC/MS)
Analysis was carried out on an Accela HPLC system interfaced to an Exactive Orbitrap mass
spectrometer (Thermo Fisher Scientific, Bremen, Germany) using a hydrophilic interaction liquid
chromatography (HILIC) column (ZIC-pHILIC, 150 × 4.6 mm, 5 µm particle size) supplied by
Hichrom Ltd. (Reading, UK). The system was initially purged by mobile phases followed by
Zic-pHILIC column conditioning at an appropriate flow rate before the sample runs were carried out.
Using standard labmethod reported previously [64], samples were randomly placed in the autosampler
tray. The ZIC-pHILICmobile phase consisted of 20mMof ammonium carbonate (Sigma-Aldrich, Poole,
UK) in purified water at pH 9.2 (solvent A) and acetonitrile (Sigma-Aldrich, Poole, UK) (solvent B) at
a flow rate of 0.3 mL/min. The elution gradient was an A:B ratio of 20:80 at 0 min, 80:20 at 30 min,
92:8 at 35 min, and finally, 20:80 at 45 min. The electro-spray ionization (ESI) interface worked in both
positive and negative ion-switching modes, with +4.0 kV of spray voltage for the positive mode and
−3.5 kV for the negative mode. The ion transfer capillary temperature was 320 ◦C, while the sheath
and auxiliary gas were set at 51 and 17 arbitrary units, respectively. The full scan range was set at
75 m/z to 1200 m/z, with the automatic gain control (AGC) target and resolution as Balanced and
High (1E6 and 50,000), respectively. Before analysis, mass calibration was done for both ESI modes
via standard Thermo Calmix solution. The signals at 83.0604 m/z (2 × ACN + H) and 91.0037 m/z
(2 × formate − H) were obtained as lock masses for both modes, respectively. Data were collected
using the Xcalibur 2.1.0 software package (Thermo Fisher Scientific, Hemel Hempstead, UK).
4.7. Data Extraction and Analysis
Using MzMatch software (IDEOM) [65] with certain specifications was used to convert the
Xcalibur peaks (see Figures S3 and S4) into numeric values, after which they could be processed and
analyzed. Metabolites were detected to the metabolomics standards initiative (MSI) levels 1 or 2,
which were primarily either based on exact mass (<three ppm deviation) plus retention time matching
to a standard, or according to accurate mass. Data were then analyzed using univariate (Excel) and
multivariate (SIMCA-P) to determine the most significant metabolites and pathways affected by
intervention. Log transformation was applied on the data prior to the analysis and filtered finally on
specific criteria (see Figures S1 and S2).
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5. Conclusions
Sustained exposure to hyperglycemia causes the metabolic disruption of pulmonary artery smooth
muscle. It can also lead to cellular damage, and could contribute to pulmonary hypertension via
enhancing the generation of free radicals and promoting the proliferation of PASMCs, which eventually
resulted in the narrowing and remodeling of the pulmonary arteries and pulmonary hypertension.
Therapeutic stabilization and the restoration targeting of pulmonary arterial smooth muscle cell
function via antioxidants treatment can demonstrate benefits for improving the redox state related to
diabetic and cardiovascular deterioration. Based on that, consistently with the importance of avoiding
ROS emerging by hyperglycemia to develop cardiovascular disease complication, antioxidants may
assist in reducing the oxidative damage straight via reacting with free radicals by scavenging them,
or indirectly by suppressing the free radical-generating enzymes or promoting intracellular antioxidant
enzymes activity, which all could slow the proliferation of PASMCs. Vitamins D and E are antioxidants
that are considered to maintain the redox state of PASMCs in the existence of an elevated glucose
condition in an in vitro setting.
Limitations and Future Prospects
Our findings were directly linked to cell-based work that is focused on the medial smooth
muscle cell, which may not be particularly applicable in an in vivo setting. Inflammatory processes
and immune system impacts were not taken into account. Thus, the reported responses in our
hyperglycemic (diabetic-like) cell culture model might differ from the hyperglycemic responses in an
in vivo setting. Therefore, it is a valuable to investigate the current study observations on an animal
model. In addition, a further increase of the glucose levels and concentrations of vitamins might be
considered in future studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/8/4/87/s1,
Table S1: Significantly changed metabolites in PASMCs resulting from treatment with HG or HG + vitamin D or E.
Figure S1: Data filtration steps. Figure S2: log2 transformation of the data improves data distribution. Figure
S3: Extracted ion traces for GSSG in HG and LG media. Figure S4: Extracted ion traces for maltotetraose and
maltopentaose in HG and LG media.
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